Are there FDA-approved Alzheimer’s blood tests to confirm the disease?

Fujirebio’s Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio test is the first Alzheimer’s blood test to receive FDA clearance, on May 16, 2025. The test is used in conjunction with an in-depth clinical history, laboratory testing, and other neurocognitive assessments to confirm a diagnosis in people whose cognitive decline is suspected to be caused by Alzheimer’s.